Larvol Delta - Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Registrational-Phase-2-QUINTESSENTIAL-Trial-of-the-Potential-FirstinClass-GPRC5DDirected-CAR-T-Cell-Therapy-Arlocabtagene-Autoleucel

Camzyos (mavacamten) - BMS

http://clinicaltrials.gov/ct2/show/NCT07807384

Sep 9, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next